Drug intelligence / Profile preview

recombinant butyrylcholinesterase (AntoXa Corporation)

Development stage
Preclinical
Lead developer
AntoXa
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous, Intramuscular
01

Overview

Recombinant butyrylcholinesterase (rBuChE) is a plant-produced enzyme being developed by AntoXa (a subsidiary of PlantForm Corporation) in collaboration with Defence Research & Development Canada (DRDC). It functions as a bioscavenger designed to protect against exposure to organophosphate nerve agents, such as sarin and soman. By binding to and neutralizing these toxic agents in the bloodstream before they can reach and inhibit endogenous acetylcholinesterase at the neuromuscular junction and in the central nervous system, rBuChE acts as a prophylactic or post-exposure treatment. The product is manufactured using a proprietary plant-based expression system (VivoExpress), which allows for rapid, scalable production of complex proteins.

Other names
rBuChErecombinant human butyrylcholinesteraseplant-made rBuChE
02

Targets

Butyrylcholinesterase

Beyond the preview

Go deeper on recombinant butyrylcholinesterase (AntoXa Corporation).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant butyrylcholinesterase (AntoXa Corporation).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call